Ricolinostat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ricolinostat
Accession Number
DB12376
Description

Ricolinostat is under investigation for the treatment of Breast Carcinoma and Metastatic Breast Cancer.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 433.512
Monoisotopic: 433.211389749
Chemical Formula
C24H27N5O3
Synonyms
  • Ricolinostat
External IDs
  • ACY-1215
  • ACY-63

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe risk or severity of QTc prolongation can be increased when Acebutolol is combined with Ricolinostat.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Ricolinostat.
AdenosineThe risk or severity of QTc prolongation can be increased when Adenosine is combined with Ricolinostat.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Ricolinostat.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ricolinostat.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Ricolinostat.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Ricolinostat.
AmifampridineThe risk or severity of QTc prolongation can be increased when Amifampridine is combined with Ricolinostat.
AmiodaroneThe risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Amiodarone.
AmisulprideThe risk or severity of QTc prolongation can be increased when Amisulpride is combined with Ricolinostat.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyrimidinecarboxylic acids and derivatives. These are compounds containing a pyrimidine ring which bears a carboxylic acid group (or a derivative thereof).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyrimidinecarboxylic acids and derivatives
Alternative Parents
Aniline and substituted anilines / Aminopyrimidines and derivatives / Heteroaromatic compounds / Secondary carboxylic acid amides / Hydroxamic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Aminopyrimidine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Heteroaromatic compound / Hydrocarbon derivative
show 10 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
WKT909C62B
CAS number
1316214-52-4
InChI Key
QGZYDVAGYRLSKP-UHFFFAOYSA-N
InChI
InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)
IUPAC Name
7-{[2-(diphenylamino)pyrimidin-5-yl]formamido}-N-hydroxyheptanamide
SMILES
ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
Not Available
PubChem Compound
53340666
PubChem Substance
347828624
ChemSpider
28536129
BindingDB
50439674
ChEBI
95073
ChEMBL
CHEMBL2364628
ZINC
ZINC000089630354
PDBe Ligand
AH4
PDB Entries
5wgl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentPainful Diabetic Peripheral Neuropathy (PDPN)1
1Active Not RecruitingTreatmentChronic, recurrent Lymphoid Leukemia1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedOtherMultiple Myeloma (MM)1
1CompletedTreatmentCarcinoma, Breast / Metastatic Breast Cancer1
1TerminatedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Carcinoma1
1WithdrawnTreatmentNon-Resectable Cholangiocarcinoma / Recurrent Cholangiocarcinoma / Stage III Extrahepatic Bile Duct Cancer / Stage III Intrahepatic Cholangiocarcinoma / Stage IIIA Hilar Cholangiocarcinoma / Stage IIIB Hilar Cholangiocarcinoma / Stage IVA Extrahepatic Bile Duct Cancer / Stage IVA Hilar Cholangiocarcinoma / Stage IVA Intrahepatic Cholangiocarcinoma / Stage IVB Extrahepatic Bile Duct Cancer / Stage IVB Hilar Cholangiocarcinoma / Stage IVB Intrahepatic Cholangiocarcinoma / Unresectable Extrahepatic Bile Duct Carcinoma1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1, 2CompletedTreatmentLymphoid Malignancies / Malignant Lymphomas1
1, 2CompletedTreatmentMultiple Myeloma (MM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.014 mg/mLALOGPS
logP3.04ALOGPS
logP3.65ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)8.91ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area107.45 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity122.73 m3·mol-1ChemAxon
Polarizability48.16 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 22:08 / Updated on February 21, 2021 18:53